A Phase II Study of Radiation Therapy and Pembrolizumab in Patients With Localized Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Dec 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 31 Aug 2018 Biomarkers information updated
- 26 Jun 2018 Planned initiation date changed from 18 May 2018 to 18 Jul 2018.